Home Healthcare Pharmaceuticals Anti Viral Drugs Market

Anti Viral Drugs Market Size, Share & Trends Analysis Report By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors, RNAi Antisense Therapeutics, Capsid Inhibitors), By Application (HIV, Hepatitis, Herpes, Influenza, Respiratory Syncytial Virus), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: October 16, 2026 | Author: Straits Research Team | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti Viral Drugs Market, By Drug Class 2025-2034 (USD MILLION/ Units)
    1. DNA Polymerase Inhibitors
    2. Reverse Transcriptase Inhibitors
    3. Protease Inhibitors
    4. Neuraminidase Inhibitors
    5. RNAi Antisense Therapeutics
    6. Capsid Inhibitors
  2. Anti Viral Drugs Market, By Application 2025-2034 (USD MILLION/ Units)
    1. HIV
    2. Hepatitis
    3. Herpes
    4. Influenza
    5. Respiratory Syncytial Virus
  3. Anti Viral Drugs Market, By Distribution Channel 2025-2034 (USD MILLION/ Units)
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy 
  4. Regional Anti Viral Drugs Market
    1. North America
      1. North America Anti Viral Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
      2. North America Anti Viral Drugs Market By Application 2025-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
      3. North America Anti Viral Drugs Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy 
      4. U.S.
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      5. Canada
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
    2. Europe
      1. Europe Anti Viral Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
      2. Europe Anti Viral Drugs Market By Application 2025-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
      3. Europe Anti Viral Drugs Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy 
      4. U.K.
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      5. Germany
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      6. France
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      7. Spain
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      8. Italy
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      9. Russia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      10. Nordic
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      11. Benelux
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      12. Rest of Europe
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
    3. APAC
      1. APAC Anti Viral Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
      2. APAC Anti Viral Drugs Market By Application 2025-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
      3. APAC Anti Viral Drugs Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy 
      4. China
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      5. Korea
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      6. Japan
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      7. India
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      8. Australia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      9. Taiwan
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      10. South East Asia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      11. Rest of Asia-Pacific
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
    4. Middle East and Africa
      1. Middle East and Africa Anti Viral Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
      2. Middle East and Africa Anti Viral Drugs Market By Application 2025-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
      3. Middle East and Africa Anti Viral Drugs Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy 
      4. UAE
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      5. Turkey
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      6. Saudi Arabia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      7. South Africa
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      8. Egypt
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      9. Nigeria
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      10. Rest of MEA
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
    5. LATAM
      1. LATAM Anti Viral Drugs Market By Drug Class 2025-2034 (USD MILLION/ Units)
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
      2. LATAM Anti Viral Drugs Market By Application 2025-2034 (USD MILLION/ Units)
        1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Respiratory Syncytial Virus
      3. LATAM Anti Viral Drugs Market By Distribution Channel 2025-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy 
      4. Brazil
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      5. Mexico
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      6. Argentina
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      7. Chile
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      8. Colombia
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
      9. Rest of LATAM
        1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        5. RNAi Antisense Therapeutics
        6. Capsid Inhibitors
        7. HIV
        8. Hepatitis
        9. Herpes
        10. Influenza
        11. Respiratory Syncytial Virus
        12. Hospital Pharmacy
        13. Retail Pharmacy
        14. Online Pharmacy 
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.